OABI vs. MXCT, ABSI, ATXS, CYH, LRMR, TVTX, PACB, ADPT, SRDX, and CELC
Should you be buying OmniAb stock or one of its competitors? The main competitors of OmniAb include MaxCyte (MXCT), Absci (ABSI), Astria Therapeutics (ATXS), Community Health Systems (CYH), Larimar Therapeutics (LRMR), Travere Therapeutics (TVTX), Pacific Biosciences of California (PACB), Adaptive Biotechnologies (ADPT), Surmodics (SRDX), and Celcuity (CELC). These companies are all part of the "medical" sector.
OmniAb (NASDAQ:OABI) and MaxCyte (NASDAQ:MXCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 8.6% of OmniAb shares are owned by company insiders. Comparatively, 3.0% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
MaxCyte has a net margin of -83.00% compared to OmniAb's net margin of -301.62%. MaxCyte's return on equity of -15.68% beat OmniAb's return on equity.
OmniAb presently has a consensus price target of $9.00, indicating a potential upside of 109.30%. MaxCyte has a consensus price target of $8.67, indicating a potential upside of 85.19%. Given OmniAb's higher possible upside, equities analysts plainly believe OmniAb is more favorable than MaxCyte.
In the previous week, MaxCyte had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for OmniAb. OmniAb's average media sentiment score of 1.88 beat MaxCyte's score of 1.25 indicating that OmniAb is being referred to more favorably in the media.
OmniAb has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
OmniAb received 7 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 100.00% of users gave OmniAb an outperform vote while only 84.62% of users gave MaxCyte an outperform vote.
MaxCyte has higher revenue and earnings than OmniAb. MaxCyte is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.
Summary
OmniAb and MaxCyte tied by winning 8 of the 16 factors compared between the two stocks.
Get OmniAb News Delivered to You Automatically
Sign up to receive the latest news and ratings for OABI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
